Hussman Strategic Advisors Inc. Lowers Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Hussman Strategic Advisors Inc. lowered its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 20.0% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,000 shares of the biopharmaceutical company's stock after selling 21,000 shares during the quarter. Hussman Strategic Advisors Inc. owned 0.07% of Catalyst Pharmaceuticals worth $2,037,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Steward Partners Investment Advisory LLC bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $27,000. Park Square Financial Group LLC bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $29,000. Sound Income Strategies LLC bought a new position in shares of Catalyst Pharmaceuticals during the 1st quarter worth about $64,000. Farther Finance Advisors LLC boosted its position in shares of Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 1,495 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 579 shares in the last quarter. Institutional investors own 79.22% of the company's stock.

Analyst Ratings Changes

Separately, Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Six equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $32.83.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Preethi Sundaram sold 2,324 shares of the business's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total value of $61,376.84. Following the transaction, the insider directly owned 42,681 shares of the company's stock, valued at approximately $1,127,205.21. The trade was a 5.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the completion of the transaction, the insider directly owned 68,873 shares in the company, valued at $1,630,912.64. This trade represents a 74.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 247,924 shares of company stock worth $5,879,369 over the last three months. 10.40% of the stock is owned by insiders.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX traded up $0.24 on Monday, hitting $21.27. The stock had a trading volume of 239,530 shares, compared to its average volume of 1,142,691. The stock has a market cap of $2.59 billion, a P/E ratio of 13.55, a price-to-earnings-growth ratio of 0.86 and a beta of 0.66. Catalyst Pharmaceuticals, Inc. has a 1 year low of $15.34 and a 1 year high of $26.58. The firm's fifty day simple moving average is $23.23 and its two-hundred day simple moving average is $22.90.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.